Veru is trading 5.95% up at $2.85 in pre-market, with no fresh company-specific announcement identified to clearly explain the move.
- Latest major updates were reported in August and appear stale as catalysts: third-quarter results, full enrollment in the 239-patient PLATEAU trial, and a potential enobosarm-semaglutide patent extending to 2044.
- Broader markets are modestly lower, so macro sentiment does not explain the rise.